Global Radioactive Diagnostic Drugs Market Growth (Status and Outlook) 2024-2030

Global Radioactive Diagnostic Drugs Market Growth (Status and Outlook) 2024-2030

The global Radioactive Diagnostic Drugs market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Radioactive Diagnostic Drugs Industry Forecast” looks at past sales and reviews total world Radioactive Diagnostic Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Radioactive Diagnostic Drugs sales for 2024 through 2030. With Radioactive Diagnostic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioactive Diagnostic Drugs industry.

This Insight Report provides a comprehensive analysis of the global Radioactive Diagnostic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radioactive Diagnostic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radioactive Diagnostic Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioactive Diagnostic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioactive Diagnostic Drugs.

United States market for Radioactive Diagnostic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Radioactive Diagnostic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Radioactive Diagnostic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Radioactive Diagnostic Drugs players cover Curium, Medi-Radiopharma, Jubilant Radiopharma, Telix and Mallinckrodt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Radioactive Diagnostic Drugs market by product type, application, key players and key regions and countries.

Segmentation by type
Single Photon Drugs
Positron Drugs
Blood Perfusion Drugs
Metabolizing Drugs
Receptor Binding Drugs
Others

Segmentation by application
Oncology
Cardiology
Neuroscience
Thyroid
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Curium
Medi-Radiopharma
Jubilant Radiopharma
Telix
Mallinckrodt
Cardinal Health
Bayer AG
GE Healthcare
Mallinckrodt Pharmaceuticals
Bracco Group

Please note: The report will take approximately 2 business days to prepare and deliver.